With the emphasis on ‘cure’, this company is dedicated to the development of novel progenitor cell-based regenerative therapeutics. It seeks to provide new treatment options to patients suffering from cardiac or peripheral vascular diseases.
Member count: 11-50
Investors 1
| Date | Name | Website |
| - | Entreprene... | entreprene... |